NCT03866525 - OH2 Oncolytic Viral Therapy in Solid Tumors | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

April 2, 2019

Primary Completion Date

August 30, 2025

Study Completion Date

August 30, 2025

Conditions

Solid TumorGastrointestinal Cancer

Interventions

BIOLOGICAL

OH2 injection, with or without irinotecan or HX008

OH2: Oncolytic Type 2 Herpes Simplex Virus Irinotecan: cytotoxic agent HX008: anti-PD-1 antibody

Trial Locations (1)

RECRUITING

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing